These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8776967)
1. [Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma]. Kakinuma H; Sasaki R; Sato K; Hirano S; Miura K; Sasaki S; Kato T Nihon Hinyokika Gakkai Zasshi; 1996 Jul; 87(7):997-1003. PubMed ID: 8776967 [TBL] [Abstract][Full Text] [Related]
2. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838 [TBL] [Abstract][Full Text] [Related]
3. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382 [TBL] [Abstract][Full Text] [Related]
4. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
5. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716 [TBL] [Abstract][Full Text] [Related]
6. [Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer]. Horiguchi A; Hatakeyama N; Ikeuchi K Hinyokika Kiyo; 1999 Jan; 45(1):31-5. PubMed ID: 10086263 [TBL] [Abstract][Full Text] [Related]
7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)]. Nakata S; Miyazawa Y; Sasaki Y; Nakano K; Takahashi H Nihon Hinyokika Gakkai Zasshi; 2010 May; 101(4):597-602. PubMed ID: 20535987 [TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. Rabbani F; Perrotti M; Bastar A; Fair WR J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699 [TBL] [Abstract][Full Text] [Related]
10. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664 [TBL] [Abstract][Full Text] [Related]
11. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. Kwak C; Jeong SJ; Park MS; Lee E; Lee SE J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy]. Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis. Zhang LM; Jiang HW; Tong SJ; Zhu HQ; Liu J; Ding Q Urol Int; 2013; 91(1):38-48. PubMed ID: 23774685 [TBL] [Abstract][Full Text] [Related]
15. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation. Song C; Kim YS; Hong JH; Kim CS; Ahn H BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666 [TBL] [Abstract][Full Text] [Related]
16. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy. Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738 [TBL] [Abstract][Full Text] [Related]
17. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer]. Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583 [TBL] [Abstract][Full Text] [Related]
19. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102 [TBL] [Abstract][Full Text] [Related]
20. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]